nelfinavir has been researched along with salubrinal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Bogaerts, E; Coucke, C; Devisscher, L; Geerts, A; Laukens, D; Libbrecht, L; Paridaens, A; Raevens, S; Van Steenkiste, C; Van Vlierberghe, H; Vandewynckel, YP; Vandierendonck, A; Verhelst, X | 1 |
2 other study(ies) available for nelfinavir and salubrinal
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Cinnamates; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Liver Neoplasms; Mice; Nelfinavir; Oligopeptides; Proteasome Inhibitors; Thiourea; Tunicamycin; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2016 |